Akers Biosciences Inc. (AKER) News
Filter AKER News Items
AKER News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AKER News Highlights
- AKER's 30 day story count now stands at 3.
- Over the past 4 days, the trend for AKER's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest AKER News From Around the Web
Below are the latest news stories about Akers Biosciences Inc that investors may wish to consider to help them evaluate AKER as an investment opportunity.
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of MergerAkers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger |
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression TrialAkers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need. |
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory BoardAkers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine. |
We Think Akers Biosciences (NASDAQ:AKER) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
SHAREHOLDER ALERT: WeissLaw LLP Reminds TLRY, CBLI, AKER and OBLN Shareholders About Its Ongoing InvestigationsTilray, Inc. (NASDAQ: TLRY) |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PAND, PRAH, AEGN, PTVCA, CRHM, CBLI, AKERHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Akers Biosciences Responds to Erroneous Earnings Call Press ReleaseAkers Biosciences, Inc. (the "Company") (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learning more about the cause of this error. |
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - RNET, PRGX, EGOV, AKER, WDR, HMSYHalper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: |
AKERS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKER and Encourages Investors to Contact the FirmNEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akers Biosciences, Inc. (NASDAQ: AKER) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by MyMD Pharmaceuticals, Inc. Click here to learn more and participate in the action. On November 12, 2020, Akers announced that it had signed an agreement to be acquired by MyMD in an all-stock merger. Pursuant to the merger agreement, at the close of the merger, Akers stockholders will own approximately 20% of the combined company. In addition, the merger agreement provides for cash and stock payments to Akers stockholders under certain circumst... |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - XLNX, IPHI, NAV, AKER, INFOHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |